Karen Tubridy | Chief Operating Officer
Abcuro, Inc.
Karen Tubridy, PharmD is the Chief Operating Officer of Abcuro, Inc. Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. Karen has responsibility for the company operations including Program Development, Manufacturing, Quality, and early Commercial activities. Karen has over 30 years’ experience in drug development strategy and operations of novel and first-in-class therapeutics. Karen previously served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She had responsibility for driving global program strategies to IND/CTA and eventual global licensure and commercial launch including several rare disease drugs.
Appearances:
Day 2 - World Orphan Drug Congress USA 2025 @ 14:40
Panel: Rare Leadership: Women redefining healthcare
"Rare Leadership: Women Redefining Healthcare," assembles four distinguished leaders from the Rare Women podcast,which launched January 11th, 2025. Each one pioneers change to improve healthcare and address critical rare disease and biopharma needs. They are united by a commitment to innovative therapies, patient-centered care, and sustainable healthcare solutions. Their backgrounds are diverse, with expertise in healthcare, biopharma, and biotech. They have unique perspectives on resolving rare disease challenges and improving healthcare for underserved communities. Their personal stories and professional insights will inspire others to shape the healthcare of tomorrow.
We’ll discuss:
Overcoming barriers in the healthcare industry
● Creating impactful solutions for rare diseases
● AI’s usefulness in healthcare innovation
● Strategies to drive meaningful change in traditionally male-dominated fields
● The power of collaboration in healthcare innovation
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events